Free Access
Med Sci (Paris)
Volume 34, Number 10, Octobre 2018
Page(s) 788 - 791
Section Le Magazine
Published online 19 November 2018
  1. Long GV, Flaherty KT, Stroyakovskiy D, et al. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol 2018 ; 28 : 1631–1639. [Google Scholar]
  2. Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 2018 ; 377 : 1345–1356. [CrossRef] [Google Scholar]
  3. Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 2018 ; 168 : 707–723. [Google Scholar]
  4. Pages C, Gornet JM, Monsel G, et al. Ipilimumab-induced acute severe colitis treated by infliximab. Melanoma Res 2013 ; 23 : 227–230. [CrossRef] [PubMed] [Google Scholar]
  5. Carswell EA, Old LJ, Kassel RL, et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975 ; 72 : 3666–3670. [CrossRef] [Google Scholar]
  6. Lienard D, Ewalenko P, Delmotte JJ, et al. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992 ; 10 : 52–60. [CrossRef] [PubMed] [Google Scholar]
  7. Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer 2009 ; 9 : 361–371. [CrossRef] [Google Scholar]
  8. Landsberg J, Kohlmeyer J, Renn M, et al. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature 2012 ; 490 : 412–416. [CrossRef] [PubMed] [Google Scholar]
  9. Zhao X, Rong L, Li X, et al. TNF signaling drives myeloid-derived suppressor cell accumulation. J Clin Invest 2012 ; 122 : 4094–4104. [CrossRef] [PubMed] [Google Scholar]
  10. Lim SO, Li CW, Xia W, et al. Deubiquitination and stabilization of PD-L1 by CSN5. Cancer Cell 2016 ; 30 : 925–939. [CrossRef] [PubMed] [Google Scholar]
  11. Bertrand F, Rochotte J, Colacios C, et al. Blocking tumor necrosis factor alpha enhances CD8 T-cell-dependent immunity in experimental melanoma. Cancer Res 2015 ; 75 : 2619–2628. [CrossRef] [Google Scholar]
  12. Bertrand F, Montfort A, Marcheteau E, et al. TNFαlpha blockade overcomes resistance to anti-PD-1 in experimental melanoma. Nat Commun 2018 ; 8 : 2256. [CrossRef] [Google Scholar]
  13. Granier C, Gey A, Dariane C, et al. Biomarqueur et cible thérapeutique en cancérologie. Med Sci (Paris) 2018 ; 34 : 231–237. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.